BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 12754622)

  • 1. The prognostic impact of hormone receptors and c-erbB-2 in pregnancy-associated breast cancer and their correlation with BRCA1 and cell cycle modulators.
    Reed W; Sandstad B; Holm R; Nesland JM
    Int J Surg Pathol; 2003 Apr; 11(2):65-74. PubMed ID: 12754622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated levels of p27, p21 and cyclin D1 correlate with positive oestrogen and progesterone receptor status in node-negative breast carcinoma patients.
    Reed W; Flørems VA; Holm R; Hannisdal E; Nesland JM
    Virchows Arch; 1999 Aug; 435(2):116-24. PubMed ID: 10599310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pregnancy and breast cancer: a population-based study.
    Reed W; Hannisdal E; Skovlund E; Thoresen S; Lilleng P; Nesland JM
    Virchows Arch; 2003 Jul; 443(1):44-50. PubMed ID: 12756565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclin D1 overexpression associates with favourable prognostic factors in invasive breast carcinoma.
    El-Hafez AA; El Aaty Shawky A; Hasan B
    Cancer Biomark; 2012; 12(4):149-54. PubMed ID: 23568005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclin D1 expression in ductal carcinoma of the breast and its correlation with other prognostic parameters.
    Ravikumar G; Ananthamurthy A
    J Cancer Res Ther; 2014; 10(3):671-5. PubMed ID: 25313758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial.
    Feldt M; Bjarnadottir O; Kimbung S; Jirström K; Bendahl PO; Veerla S; Grabau D; Hedenfalk I; Borgquist S
    J Transl Med; 2015 Apr; 13():133. PubMed ID: 25925673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas.
    Tan P; Cady B; Wanner M; Worland P; Cukor B; Magi-Galluzzi C; Lavin P; Draetta G; Pagano M; Loda M
    Cancer Res; 1997 Apr; 57(7):1259-63. PubMed ID: 9102210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case control study of novel prognostic markers and disease outcome in pregnancy/lactation-associated breast carcinoma.
    Aziz S; Pervez S; Khan S; Siddiqui T; Kayani N; Israr M; Rahbar M
    Pathol Res Pract; 2003; 199(1):15-21. PubMed ID: 12650513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer.
    Villegas SL; Darb-Esfahani S; von Minckwitz G; Huober J; Weber K; Marmé F; Furlanetto J; Schem C; Pfitzner BM; Lederer B; Engels K; Kümmel S; Müller V; Mehta K; Denkert C; Loibl S
    Breast Cancer Res Treat; 2018 Feb; 168(1):179-187. PubMed ID: 29177689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunolocalization of cyclins D and E and cyclin dependent kinase (cdk) 2 and 4 in human breast carcinoma.
    Sasano H; Frost AR; Saitoh R; Taniyama Y; Nagura H; Matsunaga G; Takehana K; Kimura M; Silverberg SG
    Anticancer Res; 1997; 17(5A):3685-90. PubMed ID: 9413224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of BRCA1 immunohistochemical localizations on prognosis of patients with sporadic breast carcinomas.
    Mylona E; Melissaris S; Nomikos A; Theohari I; Giannopoulou I; Tzelepis K; Nakopoulou L
    Pathol Res Pract; 2014 Aug; 210(8):533-40. PubMed ID: 24947414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of c-erbB2, cyclin D1 and estrogen receptor and their clinical implications in the invasive ductal carcinoma of the breast.
    Lee A; Park WC; Yim HW; Lee MA; Park G; Lee KY
    Jpn J Clin Oncol; 2007 Sep; 37(9):708-14. PubMed ID: 17940078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis.
    Vaziri SA; Krumroy LM; Elson P; Budd GT; Darlington G; Myles J; Tubbs RR; Casey G
    Clin Cancer Res; 2001 Jul; 7(7):1937-45. PubMed ID: 11448907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of 6 common antigenic markers in invasive ductal breast carcinoma: potential clinical implications.
    Lialiaris TS; Kouskoukis A; Georgiou G; Tripsianis G; Fiska A; Giatromanolaki A; Chrisafi S; Sivridis E; Vamvakopoulou DN; Soutopoulou DO; Kiritsaka A; Athanassiou E; Lialios GA; Sotiriou S; Sidiropoulos A; Vamvakopoulos NC
    Appl Immunohistochem Mol Morphol; 2011 Mar; 19(2):106-11. PubMed ID: 20724920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunolocalization of BRCA1 protein in normal breast tissue and sporadic invasive ductal carcinomas: a correlation with other biological parameters.
    Lee WY; Jin YT; Chang TW; Lin PW; Su IJ
    Histopathology; 1999 Feb; 34(2):106-12. PubMed ID: 10064388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype.
    Voduc D; Nielsen TO; Cheang MC; Foulkes WD
    Hum Pathol; 2008 Oct; 39(10):1431-7. PubMed ID: 18620730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Role of immunocytochemistry in fine needle aspiration cytology diagnosis of mammary lesions of breast].
    Di F; Wong NL
    Zhonghua Bing Li Xue Za Zhi; 2006 Dec; 35(12):738-43. PubMed ID: 17374259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Invasive micropapillary carcinoma of the breast: a clinicopathologic study of 103 cases of an unusual and highly aggressive variant of breast carcinoma.
    Gokce H; Durak MG; Akin MM; Canda T; Balci P; Ellidokuz H; Demirkan B; Gorken IB; Sevinc AI; Kocdor MA; Saydam S; Harmancioglu O
    Breast J; 2013; 19(4):374-81. PubMed ID: 23714006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of combined analysis of cyclin D1 and estrogen receptor status in breast cancer patients.
    Hwang TS; Han HS; Hong YC; Lee HJ; Paik NS
    Pathol Int; 2003 Feb; 53(2):74-80. PubMed ID: 12588434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance.
    Brennan DJ; Jirstrom K; Kronblad A; Millikan RC; Landberg G; Duffy MJ; Rydén L; Gallagher WM; O'Brien SL
    Clin Cancer Res; 2006 Nov; 12(21):6421-31. PubMed ID: 17085655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.